SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	1 Months Ended		3 Months Ended		12 Months Ended
	Sep. 30, 2016	Aug. 31, 2016	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2008
Disaggregation of Revenue [Abstract]
Total revenues			$ 7,717,132
Contract Liabilities [Abstract]
Deferred revenue						$ 100,000	$ 50,000
Earned grant revenue			$ 20,000
Inventories [Abstract]
Raw materials						2,550,515	1,767,684
Work in process						866,420	286,413
Finished goods						2,385,415	2,369,521
Inventories						5,802,350	4,423,618
Inventory valuation reserves						$ 206,000	195,000
Earnings Per Share [Abstract]
Options and warrants excluded from computation of earnings per share (in shares)			690,093	674,795
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options exercised under the plan (in shares)			119,947	10,969
Stock options, number of shares [Roll forward]
Exercised (in shares)			119,947	10,969
Stock options, outstanding, weighted average exercise price per share [Roll Forward]
Exercised (in dollars per share)			$ 4.71	$ 4.00
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period			$ 1,929,082
Exercisable, aggregate intrinsic value, end of period			$ 1,287,437
Stock Options Outstanding [Abstract]
Shares (in shares)						690,093
Average remaining contract life			3 years 9 months 18 days
Weighted average exercise price (in dollars per share)						$ 5.26
Aggregate intrinsic value			$ 1,929,082			$ 1,929,082
Stock Options Exercisable [Abstract]
Shares (in shares)						344,363
Weighted average exercise price (in dollars per share)						$ 4.31
Aggregate intrinsic value			1,287,437			$ 1,287,437
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense			97,250	$ 135,945
Revenues from External Customers [Line Items]
Net product sales			6,398,227	$ 5,427,427
Summary of accounts payable and accrued liabilities [Abstract]
Accounts payable - suppliers						2,577,968	1,494,759
Accrued commissions						214,672	126,827
Accrued royalties / license fees						421,800	429,297
Accrued payroll						343,785	187,305
Accrued vacation						301,139	309,767
Accrued bonuses						276,488	282,500
Accrued expenses - other						196,257	215,848
Total						4,332,109	3,046,303
Goodwill [Abstract]
Goodwill impairment loss			0
Goodwill [Roll Forward]
Goodwill, Beginning balance			1,666,610
Changes in foreign currency exchange rate			80,421
Goodwill, Ending balance			$ 1,747,031		$ 1,666,610
Intangible assets [Abstract]
Net Book Value						$ 1,628,239	$ 1,597,377
Taxes [Abstract]
Corporate income tax rate			21.00%		35.00%
Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues			$ 7,211,963
Non-Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues			505,169
1 to 2.79999 [Member]
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period			0
Exercisable, aggregate intrinsic value, end of period			$ 0
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)			$ 1
Range of exercise prices, maximum (in dollars per share)			$ 2.79999
Stock Options Outstanding [Abstract]
Shares (in shares)						0
Average remaining contract life			0 years
Weighted average exercise price (in dollars per share)						$ 0
Aggregate intrinsic value			$ 0			$ 0
Stock Options Exercisable [Abstract]
Shares (in shares)						0
Weighted average exercise price (in dollars per share)						$ 0
Aggregate intrinsic value			0			$ 0
2.8 to 4.59999 [Member]
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period			1,402,558
Exercisable, aggregate intrinsic value, end of period			$ 1,130,998
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)			$ 2.8
Range of exercise prices, maximum (in dollars per share)			$ 4.59999
Stock Options Outstanding [Abstract]
Shares (in shares)						309,343
Average remaining contract life			2 years 7 months 10 days
Weighted average exercise price (in dollars per share)						$ 3.47
Aggregate intrinsic value			$ 1,402,558			$ 1,402,558
Stock Options Exercisable [Abstract]
Shares (in shares)						249,968
Weighted average exercise price (in dollars per share)						$ 3.48
Aggregate intrinsic value			1,130,998			$ 1,130,998
4.6 to 6.39999 [Member]
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period			375,674
Exercisable, aggregate intrinsic value, end of period			$ 146,239
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)			$ 4.6
Range of exercise prices, maximum (in dollars per share)			$ 6.39999
Stock Options Outstanding [Abstract]
Shares (in shares)						172,875
Average remaining contract life			4 years 14 days
Weighted average exercise price (in dollars per share)						$ 5.83
Aggregate intrinsic value			$ 375,674			$ 375,674
Stock Options Exercisable [Abstract]
Shares (in shares)						63,645
Weighted average exercise price (in dollars per share)						$ 5.70
Aggregate intrinsic value			146,239			$ 146,239
6.4 to 8.19999 [Member]
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period			150,850
Exercisable, aggregate intrinsic value, end of period			$ 10,200
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)			$ 6.4
Range of exercise prices, maximum (in dollars per share)			$ 8.19999
Stock Options Outstanding [Abstract]
Shares (in shares)						161,000
Average remaining contract life			6 years 4 days
Weighted average exercise price (in dollars per share)						$ 7.06
Aggregate intrinsic value			$ 150,850			$ 150,850
Stock Options Exercisable [Abstract]
Shares (in shares)						12,000
Weighted average exercise price (in dollars per share)						$ 7.15
Aggregate intrinsic value			10,200			$ 10,200
8.2 to 10 [Member]
Stock options, additional disclosure [Abstract]
Outstanding, aggregate intrinsic value, end of period			0
Exercisable, aggregate intrinsic value, end of period			$ 0
Range of Exercise Prices [Abstract]
Range of exercise prices, minimum (in dollars per share)			$ 8.2
Range of exercise prices, maximum (in dollars per share)			$ 10
Stock Options Outstanding [Abstract]
Shares (in shares)						46,875
Average remaining contract life			3 years 2 months 8 days
Weighted average exercise price (in dollars per share)						$ 8.86
Aggregate intrinsic value			$ 0			$ 0
Stock Options Exercisable [Abstract]
Shares (in shares)						18,750
Weighted average exercise price (in dollars per share)						$ 8.86
Aggregate intrinsic value			0			$ 0
Net Product Sales [Member]
Disaggregation of Revenue [Abstract]
Total revenues			6,398,227
Net Product Sales [Member] | Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues			6,398,227
Net Product Sales [Member] | Non-Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues			0
License and Royalty Revenue [Member]
Disaggregation of Revenue [Abstract]
Total revenues			201,931
License and Royalty Revenue [Member] | Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues			201,931
License and Royalty Revenue [Member] | Non-Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues			0
R&D, Milestone and Grant Revenue [Member]
Disaggregation of Revenue [Abstract]
Total revenues			1,116,974
R&D, Milestone and Grant Revenue [Member] | Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues			611,805
R&D, Milestone and Grant Revenue [Member] | Non-Exchange Transactions [Member]
Disaggregation of Revenue [Abstract]
Total revenues			$ 505,169
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options outstanding under the plan (in shares)			810,670		810,670	690,093	810,670
Number of stock options exercised under the plan (in shares)			119,947
Assumptions made in calculating fair values of options [Abstract]
Expected term				5 years
Expected volatility				44.18%
Expected dividend yield				0.00%
Risk-free interest rate				1.58%
Stock options, number of shares [Roll forward]
Outstanding, beginning of period (in shares)			810,670
Granted (in shares)			0
Exercised (in shares)			119,947
Forfeited/expired/cancelled (in shares)			630
Outstanding, end of period (in shares)			690,093		810,670
Exercisable, end of period (in shares)			344,363
Stock options, outstanding, weighted average exercise price per share [Roll Forward]
Outstanding, beginning of period (in dollars per share)			$ 5.18
Granted (in dollars per share)			0
Exercised (in dollars per share)			4.71
Forfeited/expired/cancelled (in dollars per share)			5.56
Outstanding, end of period (in dollars per share)			5.26		$ 5.18
Exercisable, end of period (in dollars per share)			$ 4.31
Stock options, additional disclosure [Abstract]
Outstanding, weighted average remaining contractual term			3 years 9 months 18 days		3 years 8 months 8 days
Exercisable, weighted average remaining contractual term			2 years 10 months 6 days
Outstanding, aggregate intrinsic value, beginning of period			$ 2,477,853
Exercised, aggregate intrinsic value			418,655
Outstanding, aggregate intrinsic value, end of period			1,929,082		$ 2,477,853
Exercisable, aggregate intrinsic value, end of period			$ 1,287,437
Net unrecognized compensation cost						$ 634,754
Weighted average period for recognition of net unrecognized compensation cost			2 years 4 months 28 days
Total fair value of stock options vested during period			$ 333,845	$ 239,988
Stock Options Outstanding [Abstract]
Aggregate intrinsic value			2,477,853		$ 2,477,853	1,929,082	$ 2,477,853
Stock Options Exercisable [Abstract]
Aggregate intrinsic value			1,287,437			$ 1,287,437
Zika Virus [Member]
Disaggregation of Revenue [Abstract]
Maximum amount of development agreement		$ 5,900,000
Revenue from grants			400,000
Bovid TB [Member]
Disaggregation of Revenue [Abstract]
Maximum amount of development agreement	$ 700,000
Revenue from grants			$ 100,000
2008 Stock Incentive Plan [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized under the plan (in shares)						750,000		625,000
Number of stock options outstanding under the plan (in shares)			166,007			166,007
Increase in number of shares authorized (in shares)			125,000
Number of stock options exercised under the plan (in shares)			499,713
Options or shares still available to be issued (in shares)						84,280
Stock options, number of shares [Roll forward]
Exercised (in shares)			499,713
Outstanding, end of period (in shares)			166,007
2014 Stock Incentive Plan [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized under the plan (in shares)						800,000
Number of stock options outstanding under the plan (in shares)			317,218			317,218
Number of stock options exercised under the plan (in shares)			60,066
Options or shares still available to be issued (in shares)						422,716
Stock options, number of shares [Roll forward]
Exercised (in shares)			60,066
Outstanding, end of period (in shares)			317,218
Cost of Goods Sold [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense			$ 8,150	8,540
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense			11,920	53,108
Selling, General and Administrative Expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated share-based compensation expense			77,180	74,297
Africa [Member]
Revenues from External Customers [Line Items]
Net product sales			1,638,530	368,827
Asia [Member]
Revenues from External Customers [Line Items]
Net product sales			967,574	1,418,102
Europe & Middle East [Member]
Revenues from External Customers [Line Items]
Net product sales			392,070	443,045
Latin America [Member]
Revenues from External Customers [Line Items]
Net product sales			2,689,893	2,112,779
United States [Member]
Revenues from External Customers [Line Items]
Net product sales			710,160	1,084,674
CDM [Member]
Intangible assets [Abstract]
Cost						$ 2,091,908
Accumulated Amortization						463,669
Net Book Value						1,628,239
Amortization of intangible assets			$ 45,000	$ 240,000
CDM [Member] | Intellectual Property [Member]
Intangible assets [Abstract]
Cost						929,668
Accumulated Amortization						116,208
Net Book Value						813,460
CDM [Member] | Customer Contracts / Relationships [Member]
Intangible assets [Abstract]
Cost						813,459
Accumulated Amortization						101,682
Net Book Value						711,777
CDM [Member] | Order Backlog [Member]
Intangible assets [Abstract]
Cost						232,573
Accumulated Amortization						232,573
Net Book Value						0
CDM [Member] | Trade Names [Member]
Intangible assets [Abstract]
Cost						116,208
Accumulated Amortization						13,206
Net Book Value						$ 103,002